23 Nov 2023 , 02:55 PM
Lupin Limited launches world’s first fixed-dose triple combination drug, Vilfuro-G, for COPD treatment in India. Approval granted by the Drug Controller General of India for the dry powder inhaler (DPI) product.
Vilfuro-G is the only FDC combining vilanterol, fluticasone furoate, and glycopyrronium bromide for moderate to severe COPD. The product addresses the long-term management of COPD, affecting over 37 million individuals in India.
Lupin’s Q2 consolidated net profit rose 3.77-fold YoY to Rs 489.6 crore, with revenue at Rs 5038.56 crore, up 24.9% from the previous year.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.